193 related articles for article (PubMed ID: 21757001)
21. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.
Tarn C; Skorobogatko YV; Taguchi T; Eisenberg B; von Mehren M; Godwin AK
Cancer Res; 2006 May; 66(10):5477-86. PubMed ID: 16707477
[TBL] [Abstract][Full Text] [Related]
23. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
24. High CD133 expression levels in gastrointestinal stromal tumors.
Bozzi F; Conca E; Manenti G; Negri T; Brich S; Gronchi A; Pierotti MA; Tamborini E; Pilotti S
Cytometry B Clin Cytom; 2011; 80(4):238-47. PubMed ID: 21462307
[TBL] [Abstract][Full Text] [Related]
25. Impact of lipid phosphatases SHIP2 and PTEN on the time- and Akt-isoform-specific amelioration of TNF-alpha-induced insulin resistance in 3T3-L1 adipocytes.
Ikubo M; Wada T; Fukui K; Ishiki M; Ishihara H; Asano T; Tsuneki H; Sasaoka T
Am J Physiol Endocrinol Metab; 2009 Jan; 296(1):E157-64. PubMed ID: 19001549
[TBL] [Abstract][Full Text] [Related]
26. PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs).
Li J; Dang Y; Gao J; Li Y; Zou J; Shen L
Med Oncol; 2015 Apr; 32(4):111. PubMed ID: 25757539
[TBL] [Abstract][Full Text] [Related]
27. Critical role for Kit-mediated Src kinase but not PI 3-kinase signaling in pro T and pro B cell development.
Agosti V; Corbacioglu S; Ehlers I; Waskow C; Sommer G; Berrozpe G; Kissel H; Tucker CM; Manova K; Moore MA; Rodewald HR; Besmer P
J Exp Med; 2004 Mar; 199(6):867-78. PubMed ID: 15024050
[TBL] [Abstract][Full Text] [Related]
28. Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography.
Prenen H; Deroose C; Vermaelen P; Sciot R; Debiec-Rychter M; Stroobants S; Mortelmans L; Schöffski P; Van Oosterom A
Anticancer Res; 2006; 26(2A):1247-52. PubMed ID: 16619531
[TBL] [Abstract][Full Text] [Related]
29. Phosphatidylinositol 3,4,5-trisphosphate modulation in SHIP2-deficient mouse embryonic fibroblasts.
Blero D; Zhang J; Pesesse X; Payrastre B; Dumont JE; Schurmans S; Erneux C
FEBS J; 2005 May; 272(10):2512-22. PubMed ID: 15885100
[TBL] [Abstract][Full Text] [Related]
30. Lipid rafts are required for Kit survival and proliferation signals.
Jahn T; Leifheit E; Gooch S; Sindhu S; Weinberg K
Blood; 2007 Sep; 110(6):1739-47. PubMed ID: 17554062
[TBL] [Abstract][Full Text] [Related]
31. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation.
Kim WK; Park M; Kim YK; Tae YK; Yang HK; Lee JM; Kim H
Clin Cancer Res; 2011 Dec; 17(24):7584-94. PubMed ID: 22042971
[TBL] [Abstract][Full Text] [Related]
33. PTEN and SHIP2 regulates PI3K/Akt pathway through focal adhesion kinase.
Gupta A; Dey CS
Mol Cell Endocrinol; 2009 Oct; 309(1-2):55-62. PubMed ID: 19501627
[TBL] [Abstract][Full Text] [Related]
34. Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors.
Ou WB; Zhu MJ; Demetri GD; Fletcher CD; Fletcher JA
Oncogene; 2008 Sep; 27(42):5624-34. PubMed ID: 18521081
[TBL] [Abstract][Full Text] [Related]
35. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
36. [Establishment and pathologic analysis of imatinib-resistant gastrointestinal stromal tumor xenografts].
Zheng S; Wang XJ; Jia J; Pan YL; Tao DY; Lu HS; Huang KE
Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):176-80. PubMed ID: 22800481
[TBL] [Abstract][Full Text] [Related]
37. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
Antonescu CR; Besmer P; Guo T; Arkun K; Hom G; Koryotowski B; Leversha MA; Jeffrey PD; Desantis D; Singer S; Brennan MF; Maki RG; DeMatteo RP
Clin Cancer Res; 2005 Jun; 11(11):4182-90. PubMed ID: 15930355
[TBL] [Abstract][Full Text] [Related]
38. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
Bauer S; Duensing A; Demetri GD; Fletcher JA
Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
[TBL] [Abstract][Full Text] [Related]
39. Serum withdrawal-induced accumulation of phosphoinositide 3-kinase lipids in differentiating 3T3-L6 myoblasts: distinct roles for Ship2 and PTEN.
Mandl A; Sarkes D; Carricaburu V; Jung V; Rameh L
Mol Cell Biol; 2007 Dec; 27(23):8098-112. PubMed ID: 17893321
[TBL] [Abstract][Full Text] [Related]
40. Pathology of gastrointestinal stromal tumors.
Hirota S; Isozaki K
Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
